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A minor criticism of the book, is that few of the practical
protocols quoted seem to have been improved by application
in the authors' own laboratory. If one uses a technique
regularly, it is usual to come up with little ways ofimproving
the method. In this book, most of the protocols seem to be
copied unchanged from the original source. For example, in
protocol 3.11 on performing DNA measurements from para-
ffin-embedded material, the authors suggest the use of 30 ym
sections, whilst it has been recognised for some time, that
this is not the optimum and that 50 m sections often give
significantly better results. Further, many laboratories have
automated this technique, to make it quicker and more con-
venient to perform.
Although I have used Chapter 3 as an example, my im-
pression is that these criticisms apply throughout the book.
Undoubtedly, this book contains useful information but the
market for flow cytometry books is becoming more com-
petitive. From the middle of 1990 to mid-1992, at least eight
flow cytometry books have, or are scheduled to, appear on
the market. Thus, any new book needs to have a clear
objective and to be well written and organised. In my view,
this book tends to fall between stools in its aims, and could
have benefited from a better level of organisation. Given the
availability of alternative books, I would find it hard to
recommend this book to new colleagues or students.
R.S. Camplejohn
Hematopoietic Growth Factors in Clinical Applications
Edited by R. Mertelsmann and R. Herrmann, New York:
Marcel Dekker Inc., 1990, 240 pp. $99.75 (USA and
Canada), $199.50 (Others).
Since the first haemopoietic growth factors became available
for clinical testing over 5 years ago, there has been a rapid
expansion in the literature. The two editors Roland Mertels-
mann and Friedhelm Herrmann of this multi-author text,
have made major contributions to this field. They have invit-
ed contributors to initially address the biology and basic
concepts of haemopoietic growth factors before embarking
on clincial applications.
As might be expected with over 75 authors, there is some
repetition and the standard of contribution varies. The pre-
clinical chapters give a good review of the cytokines available
for testing, their production, mechanism ofaction, and recep-
tor expression. The book then naturally progresses to the
studies in sub-human primates before coming through to
man. The clinical data are predominantly from Phase I and
II trials of Granulocyte and Granulocyte-Macrophage Col-
ony Stimulating Factors, although data are presented on
Erythropoietin and Interleukin-3. This section deals mainly
with reduction in the period of neutropenia after chemo-
therapy or bone marrow transplantation, but there are also
chapters on myelodysplasia and aplastic anaemia. There is an
interesting section on the effect of colony stimulating factors
on malignant cells. This concentrates predominantly on the
potentially advantageous use of these agents to recruit mye-
loid leukaemic cells into cycle prior to chemotherapy. The
book concludes with pre-clinical data on Interleukin 4 and 6
which have just entered clinical trials.
It may be slightly too early to give firm recommendation
for the clinical indication for the use of haemopoietic growth
factors, but I felt that an attempt should have been made to
have a chapter in which the clinical data presented were
critically evaluated. Now that these agents are being market-
ed, I suspect that clinicians having read the title of this book
would have expected more guidance and help on the best
way to utilise these powerful agents in the most cost bene-
ficial manner for their patients. With the plethora of talent
and experience available from the authors contributing to
this book, it should have been possible to entice one of them
to have written this finale.
A review at this time can only be a 'snapshot' of this
rapidly progressing field. Readers will, however, find that this
review will give them an excellent basis of knowledge critic-
ally to evaluate publications as they appear. It will appeal
predominantly to clinicians wishing to rapidly assimilate the
basic science as well as the clinical results.
J.H. Scarffe
Cancer Screening
edited by A.B. Miller, J. Chamberlain, N.E. Day, M.
Hakama and P.C. Prorok, Cambridge: Cambridge University
Press, 1991, 438 pp. £45.00, $85.00.
This book is the report of a workshop 'to uptake conclusions
on screening for cancer of sites previously considered, and to
evaluate some new sites' held in April 1990 and is the fifth
monograph arising from the UICC Project on Evaluation of
Screening for Cancer. In one volume the 'State of the Art' on
screening for cancers of the breast, colorectum, cervix, ovary,
prostate, stomach, nasopharynx, and for malignant mela-
noma and neuroblastoma is brought together. Each cancer is
reported in a separate section comprising a number of
chapters (44 in all) written by 88 experts.
Each section begins with a brief summary of the state of
the art on screening for that particular cancer including a list
of recommendations for research. This is followed by a
number of chapters from different authors' presentations at
the workshop and finally an edited summary of the discus-
sion. The book is clearly laid out for reference purposes and
presents the concepts of screening straightforwardly. The
Editors state, in their Preface, that the book is targeted at
those 'interested in screening for cancer including govern-
ment and non-government organisations concerned with
cancer control' and cancer researchers. Experts in cancer-
screening may find the book rather too simple but it is
pitched at the right level for the non-expert. Those hoping
that the book will summarise the results of all the various
studies to date will be disappointed; in Chapter 1 on the UK
Trial, for example, the discussion is mainly concerned with
sensitivity, specificity and biopsy rates.
The first section on breast cancer contains five chapters
each on one of the well-known trials of screening - the UK
trial, the trials from Finland, the Swedish 2-County trial, the
Malmo trial and that from Canada. Different aspects of these
studies are described and some of the puzzling differences in
results discussed. A sixth chapter on breast self-examination
(BSE) as a strategy for downstaging in developing countries
and the importance, and feasibility, of giving adequate treat-
ment without major technological investment is unfortunately
too early to give any results of the USSR/Germany/WHO
trial. A clearly presented account ofthe principles involved in
different types of cost-effectiveness analysis completes this
section.
The section on cervical screening includes chapters on
natural history, a description of the screening programmes in
the Nordic countries indicating the stark contrast between
the success of the best-organised programmes there to the
relative lack of success of the programmes in Canada, and
indeed in the UK. The importance of 'political will' in ensur-
ing the success of national programmes and the difficulties of
reducing the overscreening of low-risk groups are rightly
emphasised. Chapter 18 contains an excellent discussion of
the evidence for the effect oftiming ofreferral for colposcopy
in terms of degree of dysplasia. While the first four chapters
in the section consider cervical screening in developing coun-
tries where as few as 5% of women may have been screened
within the previous 5 years. The enormous problems of
setting up and evaluating even the simplest of organised
programmes (which have in the past at least, defeated even-
some developed countries) are discussed. This surely must be
a major challenge for preventative medicine in the next
decade.
Sections 1 and 3 thus discuss two cancer sites where there
is sufficient evidence of the potential or actual advantages of